Shares of Schering-Plough (SGP) are down 5.1% after it says it received a 'surprising and...


Shares of Schering-Plough (SGP) are down 5.1% after it says it received a 'surprising and disappointing' FDA non-approvable letter for its post-surgery muscle relaxant sugammadex.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs